Myasthenia Gravis (MG) Treatment Market Report

Myasthenia Gravis (MG) Treatment Market Analysis, Market Size, Treatment Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2017 To 2025

  • Published Date: ---
  • Base Year for Estimate:
  • Report ID: GVR5500
  • Format: Electronic (PDF)
  • Historical Data:
  • Number of Pages: 0

The global Myasthenia Gravis (MG) treatment market is projected to exhibit strong growth through the forecast period. The MG treatment market is driven by a strong pipeline comprising of around 19 drug candidates, increased focus on R&D of biologics, growing awareness and adoption of novel therapies, favorable investment scenario, healthcare facilities, and reimbursement policies in developed economies. Furthermore, emerging targeted therapies and symptom based therapies are believed to present significant market opportunity in the treatment of myasthenia gravis.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that leads to varying degrees of skeletal muscle weakening in the eyes, face, and throat. This rare disease is caused due to communication loss between the nerve cells and muscles causing difficulties in the relaxation and contraction of muscles controlling the eyes and eyelids, speaking, chewing, and facial expressions. Myasthenia gravis is the most common type of neuromuscular disorder according to the Myasthenia Gravis Foundation of America. In the U.S., the prevalence of myasthenia gravis is around 14 - 20 cases per 100,000 people.

Myasthenia gravis remains an incurable disease despite the current treatment options that include surgery, intravenous therapies, autologous stem cell transplants, and medications such as cholinesterase inhibitors and immunosuppressants. Some of the drugs used for MG treatment are Mestinon and immunotherapeutic agents such as Imuran, Neoral,Solaris, and CellCept.The key players for myasthenia gravis treatment market include: Novartis Pharmaceuticals Corporation, Grifols SA, Pfizer, GlaxoSmithKline plc, Bristol-Myers Squibb Company, AbbVie Inc., Valeant Pharmaceuticals International, F. Hoffmann Roche La Ltd., RPG Life Sciences, Biogen Inc., and others. 

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified